Molecular similarity considerations in the licensing of orphan drugs.
View/ Open
Date
2017-02-01ICR Author
Author
Franco, P
Porta, N
Holliday, JD
Willett, P
Type
Journal Article
Metadata
Show full item recordAbstract
The large costs associated with modern drug discovery mean that governments and regulatory bodies need to provide economic incentives to promote the development of orphan drugs (i.e., medicinal products that are designed to treat rare disease that affect only small numbers of patients). Under European Union (EU) legislation, a medicine can only be authorised for treating a specific rare disease if it is not similar to other orphan drugs already authorised for that particular disease. Here, we discuss the use of 2D fingerprints to calculate the Tanimoto similarity between potential and existing orphan drugs for the same disease, and present logistic regression models correlating these computed similarities with the judgements of human experts.
Collections
Subject
Humans
Molecular Structure
Legislation, Drug
Orphan Drug Production
Research team
Clinical Trials & Statistics Unit
Language
eng
Date accepted
2016-11-30
License start date
2017-02
Citation
Drug discovery today, 2017, 22 (2), pp. 377 - 381
Publisher
ELSEVIER SCI LTD